Floatz logo

Ubamatamab

Endometrial Cancer

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Endometrial Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BBB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Eli Lilly and Company
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Ubamatamab is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →